Biocon - Maiden Foray Into Vaccines Via Serum Alliance: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has approved the merger of Covidshield Technologies Ltd., subsidiary of Serum Institute Life Sciences with Biocon Biologics.
The company also entered into a strategic alliance with Serum Institute with an offer of 15% stake in Biocon Biologics with post money valuation of the company ~ $4.9 billion.
The alliance gives the company access to 100 million doses of vaccines/annum for 15 years with commercialisation rights (including Covid-19 vaccines) for global markets.
The strategic alliance will also develop antibodies along with a service level agreements for manufacturing and distribution of the vaccines and antibodies.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.